Mutant p53 and mTOR/PKM2 regulation in cancer cells. (Q38759452)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27385486%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

title

Mutant p53 and mTOR/PKM2 regulation in cancer cells (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27385486%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27385486%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

Massimo Donadelli

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27385486%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

author name string

Ilaria Dando

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27385486%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

publication date

7 July 2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27385486%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27385486%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

volume

68

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27385486%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27385486%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

page(s)

722-726

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27385486%20AND%20SRC:MED&resulttype=core&format=json

Discovery and saturation analysis of cancer genes across 21 tumour types

17 March 2020

cites work

1 reference

Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome.

21 January 2018

1 reference

Novel targets and interaction partners of mutant p53 Gain-Of-Function

21 January 2018

1 reference

Mutant p53 Drives Cancer by Subverting Multiple Tumor Suppression Pathways

21 January 2018

1 reference

mTOR: from growth signal integration to cancer, diabetes and ageing

21 January 2018

1 reference

Pyruvate kinase M2-specific siRNA induces apoptosis and tumor regression

21 January 2018

1 reference

A system for stable expression of short interfering RNAs in mammalian cells

21 January 2018

1 reference

Mutant p53 proteins counteract autophagic mechanism sensitizing cancer cells to mTOR inhibition.

21 January 2018

1 reference

Gain-of-function mutant p53 promotes cell growth and cancer cell metabolism via inhibition of AMPK activation.

21 January 2018

1 reference

Mutant p53 Amplifies Epidermal Growth Factor Receptor Family Signaling to Promote Mammary Tumorigenesis.

21 January 2018

1 reference

Mutant p53 enhances MET trafficking and signalling to drive cell scattering and invasion

21 January 2018

1 reference

Death-associated protein kinase 1 promotes growth of p53-mutant cancers

21 January 2018

1 reference

Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1

21 January 2018

1 reference

Nuclear PKM2 regulates β-catenin transactivation upon EGFR activation

21 January 2018

1 reference

Nuclear PKM2 regulates the Warburg effect.

21 January 2018

1 reference

Pyruvate kinase M2 regulates gene transcription by acting as a protein kinase

21 January 2018

1 reference

Pyruvate kinase M2 facilitates colon cancer cell migration via the modulation of STAT3 signalling

21 January 2018

1 reference

Double mutant P53 (N340Q/L344R) promotes hepatocarcinogenesis through upregulation of Pim1 mediated by PKM2 and LncRNA CUDR

21 January 2018

1 reference

Pyruvate kinase M2 and cancer: an updated assessment

21 January 2018

1 reference

Gain-of-function mutant p53 downregulates miR-223 contributing to chemoresistance of cultured tumor cells.

21 January 2018

1 reference

Mutant p53 stimulates chemoresistance of pancreatic adenocarcinoma cells to gemcitabine

21 January 2018

1 reference

Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment

21 January 2018

1 reference

The mTOR signaling pathway is an emerging therapeutic target in multiple myeloma.

21 January 2018

1 reference

Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth

21 January 2018

1 reference

Pyruvate kinase isoform M2 (PKM2) participates in multiple myeloma cell proliferation, adhesion and chemoresistance

21 January 2018

1 reference

Pyruvate kinase isoenzyme M2 is a therapeutic target of gemcitabine-resistant pancreatic cancer cells.

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/IUB.1534

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27385486%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

1 reference